Americans Should Celebrate China's Biotech Revolution
The article argues that China's rapid advances in biotechnology, including gene editing, stem cell research, and biomanufacturing, should be welcomed rather than feared by Americans, as these developments could lower drug costs, accelerate medical breakthroughs, and benefit global health—provided the U.S. focuses on competing through innovation rather than protectionism.
Background
- Richard Hanania is a conservative commentator and lawyer who writes about politics, law, and US-China competition; his Substack "Racket News" often argues that the US should adopt a pragmatic rather than alarmist stance toward China.
- This essay contends that China's rapid advances in biotechnology (e.g., gene editing, synthetic biology, drug development) are wrongly framed as a threat — and that Americans should actually celebrate them, because breakthroughs in medicine and longevity help all of humanity regardless of which country achieves them first.
- Hanania is pushing back against the dominant "decoupling" and "technological nationalism" narrative in Washington, which treats Chinese scientific progress as a national-security danger to be blocked or contained.
- The piece connects to broader debates: the US-CHINA tech war, COVID-era rivalry over vaccine research, restrictions on Chinese biotech firms like BGI, and the ideological question of whether knowledge and medical innovation are zero-sum or positive-sum goods.